Krystal Biotech’s (KRYS) Buy Rating Reaffirmed at HC Wainwright

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $310.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 1.21% from the company’s current price.

Other equities analysts also recently issued reports about the stock. Weiss Ratings upgraded shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, April 9th. Wall Street Zen upgraded shares of Krystal Biotech from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Chardan Capital raised their price target on Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. The Goldman Sachs Group raised their price target on Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Finally, Zacks Research downgraded Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Krystal Biotech has an average rating of “Moderate Buy” and a consensus price target of $324.11.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $306.29 on Monday. The company has a market cap of $9.03 billion, a price-to-earnings ratio of 40.95 and a beta of 0.50. The stock has a 50 day simple moving average of $268.10 and a 200-day simple moving average of $253.74. Krystal Biotech has a 12-month low of $122.80 and a 12-month high of $319.48.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The business had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. On average, equities analysts forecast that Krystal Biotech will post 7.98 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $263.21, for a total value of $6,580,250.00. Following the completion of the sale, the insider directly owned 1,403,155 shares in the company, valued at approximately $369,324,427.55. The trade was a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Dino A. Rossi sold 18,950 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $261.41, for a total value of $4,953,719.50. Following the sale, the director directly owned 78,691 shares of the company’s stock, valued at approximately $20,570,614.31. This trade represents a 19.41% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 116,664 shares of company stock valued at $31,136,828. 13.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors have recently added to or reduced their stakes in the company. UMB Bank n.a. grew its position in Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after acquiring an additional 37 shares during the period. Optimize Financial Inc grew its stake in Krystal Biotech by 1.4% during the fourth quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock worth $704,000 after buying an additional 40 shares during the period. Perigon Wealth Management LLC grew its stake in Krystal Biotech by 0.5% during the fourth quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock worth $2,211,000 after buying an additional 41 shares during the period. Regal Investment Advisors LLC grew its stake in Krystal Biotech by 1.0% during the fourth quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock worth $1,075,000 after buying an additional 44 shares during the period. Finally, Torray Investment Partners LLC grew its stake in Krystal Biotech by 0.4% during the first quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock worth $3,108,000 after buying an additional 47 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.